Popular Trials
Vitamin A Derivative
ALK-001 for Stargardt Disease
Recruiting3 awardsPhase 2
Somerville, Massachusetts
This trial tests a special type of vitamin A called ALK-001 to see if it can safely slow down vision loss in people with Stargardt disease by reducing harmful substances in the eye. ALK-001 is designed to reduce the accumulation of toxic substances in the retina, which are associated with vision loss in Stargardt disease.
Popular Filters
Trials for STGD Patients
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
Recruiting1 award8 criteria
Westport, Connecticut
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Trials for Age-Related Macular Degeneration Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
Recruiting1 award4 criteria
Birmingham, Alabama
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
Recruiting1 awardPhase 1 & 2
Mesa, Arizona
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Trials for ABCA4 Positive Patients
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Gene Therapy
OCU410ST for Stargardt Disease
Recruiting1 awardPhase 1 & 2
Bellaire, Texas
This trial tests OCU410ST, a treatment using a harmless virus to deliver a helpful gene into the eye, for children and young adults with Stargardt disease. The gene helps manage fat buildup, stress, and inflammation in the eye.
Tinlarebant for Stargardt Disease
Recruiting1 awardPhase 3
Palo Alto, California
This trial is testing a medication called tinlarebant to see if it can slow down eye damage in teenagers with a condition called STGD1. About 90 participants will take tinlarebant for an extended period. The goal is to see if tinlarebant can help prevent their vision from getting worse.
Trials With No Placebo
Behavioural Intervention
Scotoma Awareness Training for Low Vision
Recruiting1 award4 criteria
Birmingham, Alabama
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
Recruiting1 awardPhase 1 & 2
Mesa, Arizona
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.